A prospective randomized study to assess the optimal duration of intravenous antimicrobial prophylaxis in elective gastric cancer surgery

Int Surg. 2012 Apr-Jun;97(2):169-76. doi: 10.9738/CC91.1.

Abstract

The duration of antimicrobial prophylaxis in gastric cancer surgery is not yet established. This prospective randomized study was performed to confirm the noninferiority of single-dose versus multiple-dose antimicrobial prophylaxis in terms of the incidence of surgical-site infection in gastric cancer surgery. Three hundred twenty-five patients undergoing elective resection for gastric cancer were randomized to receive only single-dose cefazolin (1 g) during surgery (single-dose group) or an additional 5 doses every 12 hours postoperatively (multiple-dose group). The overall incidence of surgical-site infections was 9.1% in the single-dose group and 6.2% in the multiple-dose group [difference (95% confidence interval): -2.9% (-5.9%-0.0%)]. Multivariate logistic regression analysis identified blood loss, being overweight, and advanced age as significant independent risk factors for surgical-site infection. Single-dose antimicrobial prophylaxis seemed to be acceptable, and choosing multiple-dose prophylaxis may have little impact on the prevention of surgical-site infections in elective gastric cancer surgery.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Antibiotic Prophylaxis / methods*
  • Cefazolin / therapeutic use*
  • Drug Administration Schedule
  • Elective Surgical Procedures*
  • Female
  • Follow-Up Studies
  • Gastrectomy*
  • Humans
  • Incidence
  • Intraoperative Care / methods
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Postoperative Care / methods
  • Prospective Studies
  • Risk Factors
  • Stomach Neoplasms / surgery*
  • Surgical Wound Infection / epidemiology
  • Surgical Wound Infection / etiology
  • Surgical Wound Infection / prevention & control*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Cefazolin